Participated · Series G · Aug 2026

Form Energy develops iron-air long-duration batteries capable of delivering up to 100 hours of discharge. Its chemistry relies on iron oxidation and reduction, enabling lower-cost storage by avoiding higher-priced minerals like lithium, cobalt, and nickel. The company has secured large commercial customers including Google, Crusoe, Xcel Energy, and FuturEnergy Ireland and reports a commercial project backlog of about 80 gigawatt-hours. About 80% of the company’s materials supply is sourced from the U.S., with the remainder from Europe and Asia. Form is expanding manufacturing capacity in West Virginia following its recent financing. The company’s positioning and technology aim to address growing demand for long-duration storage as U.S. electricity demand rises and renewable generation expands.

Participated · Series B · Jul 2026

Databento provides a unified API delivering real-time and historical market data across futures, options, and equities, owning the market data stack end-to-end and colocating servers at exchanges to capture data directly. The company emphasizes performance, reliability, and a developer-friendly experience, and reports more than doubled active API users in recent months. Financially, Databento reached profitability with 24 employees, grew revenue 6.65x year over year, and has maintained over 97% enterprise logo retention since inception. It plans to expand its infrastructure footprint to more than 20 data centers worldwide and has secured over 100 petabytes of additional storage capacity. Databento aims to broaden coverage across asset classes and geographies as part of its growth strategy.

Participated · Seed · May 2024

Pascal develops a novel class of solid refrigerants and systems for heat pumps, air conditioners and refrigeration that operate at much lower pressures than prior solid‑refrigerant approaches. Its technology targets commercial and residential HVAC and refrigeration, promising 0 direct refrigerant emissions and 50%–80% improvements in energy efficiency while enabling smaller, quieter and safer systems. Pascal says its systems can interface directly with standard HVAC components and be manufactured using off‑the‑shelf parts from the existing supply chain. The company plans to productize its low‑pressure solid refrigerant system to meet commercial HVAC specifications and to expand its Boston‑based team of mechanical engineers, chemists, and material scientists. Pascal launched from the Mason Group at Harvard University and lists Adam Slavney (co‑founder & CEO), Jinyoung Seo (co‑founder & CTO) and Jarad Mason (co‑founder & Chief Science Officer) as founders. Financially, the company announced an $8 million seed raise to support productization and team growth.

Participated · Seed · Oct 2023

Osmoses has developed a patented membrane technology and polymer material platform that delivers unprecedented flux and selectivity for separating the world’s smallest gas molecules. The company says its membranes can reduce industrial energy consumption by up to 90%, enable up to 40% higher product recoveries in some hydrogen purification applications, and cut footprint by over 50% versus conventional processes. Published in Science Magazine in 2022, the platform targets difficult, energy‑intensive separations across hydrogen, biomethane, oxygen generation, helium harvesting, refrigerant reuse, and carbon capture. Osmoses plans to develop commercial-scale membrane modules for field deployment and establish pilot partnerships with chemical and petrochemical firms, utilities, and alternative energy companies. In the coming months the company will double full-time headcount and build partnerships with engineering and manufacturing firms to commercialize its technology. Founded in 2021 and spun out of MIT, Osmoses aims to address a gas separations market the company projects to grow from $15 billion toward $35 billion by 2030. Osmoses has developed a patented 3D ladder membrane polymer platform that delivers up to 5x the selectivity and 100x the permeability versus conventional membranes, while remaining stable under industrial conditions. The membranes are designed to integrate with existing energy infrastructures and are manufactured via established techniques as modular units. The company says the platform can cut energy consumption by 40%–60% compared with commercial alternatives and targets separations including methane, hydrogen, oxygen, biogas upgrading, and CO2 removal. Osmoses positions its technology as a lower-cost, higher-performance alternative to thermal separation processes with applications across power generation and materials manufacturing. The team plans to use initial funding to hire technical and operations staff, advance platform development, scale manufacturing, and pursue initial commercial partnerships. Founded in 2021 and spun out of MIT, Osmoses is based in Cambridge, Mass.

Participated · Seed · Oct 2022

Axoft develops implantable brain-computer interfaces (iBCIs) built from its proprietary bio-inspired Fleuron™ material, designed to improve biocompatibility and neural data quality. Fleuron is reported to be up to 10,000x softer than polyimide, offers greater region access and higher sensor/stimulator density per thread, and reduces signal attenuation versus standard flexible probes. The company has demonstrated first-in-human implants in more than 11 patients and completed a study at The Panama Clinic with four patients undergoing tumor resection, recording cortical and subcortical activity. Axoft has research published in Nature (December 2023 and June 2025) showing scalable single-cell electrophysiology enabled by its materials and interfaces. The company has commercialized Fleuron via an exclusive licensing agreement with Stanford and secured a joint development agreement with Kayaku Advanced Materials, alongside grant funding to build a GMP manufacturing facility. Co-founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft has opened a subsidiary in Grenoble, France, and plans to scale manufacturing and expand engineering, microfabrication and chemistry teams as it advances clinical programs and regulatory work.